Decreased risk of developing cancer in subjects carrying SLC52A3 rs13042395 polymorphism: proof from a meta-analysis

Biomark Med. 2016 Oct;10(10):1105-1118. doi: 10.2217/bmm-2016-0158. Epub 2016 Sep 7.

Abstract

Aim: This study aimed to conduct a meta-analysis to explore the association between SLC52A3 rs13042395 polymorphism and cancer risk.

Materials & methods: A comprehensive literature search was performed to confirm the relationship evaluated using STATA 12.0 software.

Results: Overall, SLC52A3 rs13042395 C>T polymorphism was associated with cancer risk in two genetic models (TT vs CC: odds ratio: 0.86; 95% CI: 0.80-0.93; p < 0.001, TT vs CC + CT: odds ratio: 0.88; 95% CI: 0.82-0.95; p = 0.001). Significant associations were found between SLC52A3 rs13042395 polymorphism and decreased cancer risk among esophageal cancer, Asians, female, normal BMI and old age groups. No significant associations were observed in alcohol and smoking groups.

Conclusion: SLC52A3 rs13042395 C>T polymorphism might be a potential biomarker for cancer susceptibility.

Keywords: SLC52A3; association; cancer; meta-analysis; rs13042395.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Asian People / genetics
  • Databases, Factual
  • Disease Susceptibility
  • Esophageal Neoplasms / etiology
  • Esophageal Neoplasms / genetics
  • Esophageal Neoplasms / pathology*
  • Genotype
  • Homozygote
  • Humans
  • Membrane Transport Proteins / genetics*
  • Membrane Transport Proteins / metabolism
  • Odds Ratio
  • Polymorphism, Single Nucleotide
  • Risk Factors

Substances

  • Membrane Transport Proteins
  • SLC52A3 protein, human